Analysis and treatment options for small cell lung cancer
Molecular Landscape Analysis and Clinical Implications for SCLC
Shanghai Chest Hospital · NCT05945745
This study looks at small cell lung cancer to see how its unique features can help doctors find better treatments and predict how well patients will respond to new therapies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Shanghai Chest Hospital (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT05945745 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on small cell lung cancer (SCLC), an aggressive form of lung cancer known for rapid growth and early metastasis. It aims to explore the molecular characteristics and immunologic microenvironment of SCLC to improve disease classification and treatment strategies. By identifying molecular alterations, the study seeks to enhance predictions of patient response to novel therapies and ongoing clinical trials. The research highlights the need for reliable biomarkers to improve long-term outcomes for patients with SCLC.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a histologically proven diagnosis of small cell lung cancer.
Not a fit: Patients with non-small cell lung cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and better survival rates for patients with small cell lung cancer.
How similar studies have performed: While there have been advancements in understanding SCLC, this study's specific focus on molecular alterations and their implications for treatment is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically proven diagnosis of SCLC * 18 years of age or older * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Histologically proven diagnosis of non-SCLC
Where this trial is running
Shanghai
- Shanghai Chest Hospital — Shanghai, China (RECRUITING)
Study contacts
- Study coordinator: Xiaomin Niu
- Email: ar_tey@hotmail.com, artey@sjtu.edu.cn
- Phone: 021-22200000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Small-cell Lung Cancer, Small Cell Lung Cancer, Combined Type, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Limited Stage